Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature.

Document Type

Article

Publication Date

3-1-2024

Publication Title

Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology

Keywords

Humans; Hepatoblastoma; Prospective Studies; Risk Factors; Incidence; Neoplasms, Second Primary; Hematologic Neoplasms; Liver Neoplasms; washington; spokane; pshmc

Abstract

Treatment intensification has improved survival in patients with hepatoblastoma (HB); however, these treatments are associated with an increased risk of late effects, including second malignant neoplasms (SMNs). Data is limited regarding SMNs following HB treatment. Cases of SMNs following treatment for HB reported in the literature and from personal communication were analyzed to further assess this late effect. Thirty-eight patients were identified. The median age at diagnosis of HB was 16 months (range: 3 to 168 mo). All patients had received a platinum agent, and almost all had anthracycline exposure. The SMNs reported were hematopoietic malignancies (n=19), solid tumors (n=12), and post-transplant lymphoproliferative disorder (n=7). Of the 36 patients with outcome data, 19 survived. SMNs following HB treatment were primarily seen in patients with chemotherapy exposure, a history of liver transplantation, hereditary tumor predisposition syndromes, and/or a history of radiation treatment. Hematopoietic malignancies were the most common SMN reported in this cohort and were diagnosed earlier than other SMNs. Prospective collection of data through a companion late effects study or international registry could be used to further evaluate the rates and risks of SMNs as well as tumor predisposition syndromes in patients treated for HB.

Clinical Institute

Women & Children

Department

Pediatrics

Department

Hematology

Department

Oncology

Link to Full Text

PSJH Full Text

Share

COinS